Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Shareprice 35% below pp price
View:
Post by Turtle4 on Mar 27, 2024 11:34am

Shareprice 35% below pp price

0.65
Come on howie, how are you going to get people to take part in the private Placement?
Comment by lscfa on Mar 27, 2024 12:06pm
Asking TSXV approval to reprice?
Comment by forhandlaren on Mar 27, 2024 12:18pm
The current private placement was a great mistake by management. They had already secured cash for another 6 to 7 months by tax returns and loan. Why not wait for some excitment over the new plans kick in? Possibly also an anti-aging deal for a region they won't launch in. I think that potential participants tried to sell shares in order to finance their participation with warrents attached ...more  
Comment by tylerreddick on Mar 27, 2024 12:26pm
" I think that potential participants tried to sell shares in order to finance their participation " ==================================== Why do you keep repeating that nonsense. SBM only trades a handful of shares per day, how on earth could someone buying into the PP sell into that simple fact?
Comment by biorun on Mar 27, 2024 2:36pm
Some smaller hands may have in fact done this, but certainly has not had a profound impact. I would say the lower share price is helpful if one wants to take a reasonable risk and double one's money. There is fundamentally nothing different between when we trading at 13-14 cents vs now.  Seen it so many times before play out. Buy low, sell high, that's how money is made on penny ...more  
Comment by MirrorWorldMan on Mar 27, 2024 2:39pm
I genuinely think that Howie only needs to produce numbers or even dates for the AbbVie deal. At least provide guidance to when when this dumb company is forecasted to be profitable. Silence perpetuates negative speculation and zero valuations. 
Comment by tylerreddick on Mar 27, 2024 10:21pm
Howie handed total control over the AbbVie in that "wonderful" deal he negotiated, and AbbVie doesn't give a rat's behind whether SBM survives or not. They probably would prefer that we didn't, then they could just steal 1067 from us. So don't expect anything about that for a while yet.
Comment by Pandora on Mar 27, 2024 11:30pm
Someone feeling bad re management may want to have a look at C.CISC and their struggles - starting with an open letter to shareholders on Feb 23 from Hummingboard Capital. It's pretty much all in the bulletin board.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities